在现场形成酶响应性-水凝:一种先进的长效注射药物输送系统
Sophie M Coulter1, Sreekanth Pentlavalli1, Yuming An1
1Biofunctional Nanomaterials Group, School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast, Co. Antrim BT9 7BL, N. Ireland.
Journal of the American Chemical Society
|June 26, 2024
概括
这项研究开发了一种新的可注射水凝储存器,用于长效药物输送. 该系统在35天内释放抗逆转录病毒性齐多夫丁 (AZT),改善患者的坚持和减少最初的药物爆发.
科学领域:
- 生物材料科学
- 药物输送系统
- 纳米技术
背景情况:
- 长效药物输送系统通过提供持续的药物释放来提高患者的坚持.
- 可以注射的存储器提供了一个替代口服方案,简化了治疗方案.
研究的目的:
- 开发和验证一个优化的现场形成可注射仓库,用于持续的药物输送.
- 为了证明低分子量药物可控释放的类配方的可行性.
主要方法:
- 用于皮下注射的--药物合物 ((NPhe) 4GGGGk(AZT) y(p) -OH) 的配方.
- 使用振荡性质学和使用小角度中子散射的结构来描述水凝形成动力学.
- 药物释放特征和体外蛋白酶耐药性的评估.
主要成果:
- 这种配方在皮肤酸酶触发后,在几秒钟内形成水凝储存.
- 在Sprague- Dawley大鼠中,持续释放齐多夫丁 (AZT) 达到了35天,维持治疗度.
- 类结构提供了蛋白酶耐药性,并通过结水解降低了初始药物爆发.
结论:
- 开发的类注射库是长效药物输送的有希望的平台.
- 这种系统有效地提供抗逆转录病毒药物,有可能改善治疗的坚持和结果.
- 这种配方的快速凝结,持续释放和蛋白质酶耐药性突出显示了其治疗潜力.
更多相关视频
相关概念视频
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
336
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
336
Modified-Release Drug Delivery Systems: Rate-Programmed II
139
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
139
Modified-Release Drug Delivery Systems: Stimuli-Activated
184
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
184
Oral Drug Delivery Systems: Continuous-Release Systems
319
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
319
Oral Drug Delivery Systems: Delayed-Release Systems
228
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
228
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
211
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
211


